/* mobile /* end mobile MEDDESKTOP: B. Braun Medical Inc. Recalls All Lots and All Sizes of Pre-Filled Heparin and Normal Saline Flush Syringes

Wednesday, January 23, 2008

B. Braun Medical Inc. Recalls All Lots and All Sizes of Pre-Filled Heparin and Normal Saline Flush Syringes

B. Braun's Supplier Prompts Voluntary Recall of All Lots and All Sizes of Pre-Filled Heparin and Normal Saline Flush Syringes
AM2PAT Inc. manufactures these pre-filled syringes under both its private label, Sierra Pre-Filled Inc., as well as under the B. Braun Medical Inc. label

Contact:
Stephanie Euler, 908-276-4344 ext. 213
Susan Denby, 610-997-4856

FOR IMMEDIATE RELEASE -- January 18, 2008 -- B. Braun Medical Inc. was recently notified by its contract manufacturer, AM2PAT Inc., of a nationwide recall of all lots and sizes of Pre-filled Heparin and Saline Flush Syringes.

Catalog #

Lot #

Description

513584

All

Normal Saline 3mL in 12 mL Syringe

513586

All

Normal Saline 5mL in 12 mL Syringe

513587

All

Normal Saline 10mL in 12 mL Syringe

513610

All

10 units/mL Heparin, 5mL in 12 mL Syringe

513611

All

100 units/mL Heparin, 3mL in 12 mL Syringe

513612

All

100 units/mL Heparin, 5mL in 12 mL Syringe

Customers that have the recalled product in their possession should discontinue use immediately. If patients report any problems that may be related to usage of this product a physician should be contacted. Customers may contact the B. Braun Medical Inc. Customer Support Department at (800) 227-2862, Monday through Friday, 8 AM to 7 PM EST for instructions for handling the affected product and to arrange for replacement product.

Based on ongoing FDA inspection of AM2PAT Inc.'s facility, and CDC investigation it has been determined that there is a potential for the sterility of these affected products to be compromised, which may result in potential contamination. AM2PAT previously initiated a recall of one lot of Sierra Pre-Filled Heparin (lot #070926H) that was found to be contaminated with Serratia marcescens, which may lead to patient infections. CDC has confirmed growth of Serratia marcescens from several unopened syringes of this product in this specific AM2PAT lot. This type of bacterial infection could present a serious adverse health consequence that could lead to life-threatening injuries and/or death.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to MedWatch 5600 Fishers Lane, Rockville, MD 20852-9787
  • Fax: 1-800-FDA-0178

tag: , , , , , , , ,

No comments:

LinkWithin

Related Posts Widget for Blogs by LinkWithin